News Releases

Feb 28, 2023
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
Financial
Feb 22, 2023
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
Financial
Feb 09, 2023
Myriad Genetics to Participate in Upcoming Healthcare Conferences
Financial
Jan 04, 2023
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Corporate
Nov 01, 2022
Myriad Genetics Reports Third Quarter Financial Results
Financial
Oct 26, 2022
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
Financial
Aug 04, 2022
Myriad Genetics Reports Second Quarter Financial Results
Financial
Jul 28, 2022
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
Financial
Jul 19, 2022
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022
Financial
May 05, 2022
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
Financial
Apr 28, 2022
Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022
Financial
Feb 24, 2022
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Financial
Feb 16, 2022
Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022
Corporate
Jan 05, 2022
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference
Corporate
Nov 02, 2021
Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans
Financial